Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Combo Product GMP Reg Speeds Ahead Unchanged

This article was originally published in The Gold Sheet

Executive Summary

Agency decides to keep the proposed rule, issued in 2009, “largely identical” and denies requests to delay implementation a year.

You may also be interested in...

FDA Combination Products Office Finalizing Manufacturing, Adverse Event Rules

FDA's Office of Combination Products is also developing guidance on how to determine whether a medical product is a device, drug or biologic.

Company Questions Remain Unanswered In FDA's Combo Products GMP Rule

Agency's proposed "streamlined approach" to combination product manufacturing raises a number of practical questions, such as what elements are actual components of a combo product and at what stage the streamlined system kicks in, firms say.

Patient-Focused Drug Development, Complex Trial Design May Not Get More Funding In PDUFA VII

US FDA proposed increasing staffing and resources for both programs during the next user fee program cycle, but industry representatives did not believe it necessary.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts